RT Journal Article
SR Electronic
T1 Safety and immunogenicity of a SARS-CoV-2 recombinant protein vaccine with AS03 adjuvant in healthy adults: interim findings from a phase 2, randomised, dose-finding, multi-centre study
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.10.08.21264302
DO 10.1101/2021.10.08.21264302
A1 Sridhar, Saranya
A1 Joaquin, Arnel
A1 Bonaparte, Matthew I
A1 Bueso, Agustin
A1 Chabanon, Anne-Laure
A1 Chen, Aiying
A1 Chicz, Roman M.
A1 Diemert, David
A1 Essink, Brandon J
A1 Fu, Bo
A1 Grunenberg, Nicole A
A1 Janosczyk, Helene
A1 Keefer, Michael C
A1 Rivera M, Doris M
A1 Meng, Ya
A1 Michael, Nelson L.
A1 Munsiff, Sonal S
A1 Ogbuagu, Onyema
A1 Raabe, Vanessa N
A1 Severance, Randall
A1 Rivas, Enrique
A1 Romanyak, Natalya
A1 Rouphael, Nadine G
A1 Schuerman, Lode
A1 Sher, Lawrence D
A1 Walsh, Stephen R
A1 White, Judith
A1 von Barbier, Dalia
A1 de Bruyn, Guy
A1 Canter, Richard
A1 Grillet, Marie-Helene
A1 Keshtkar-Jahromi, Maryam
A1 Koutsoukos, Marguerite
A1 Lopez, Denise
A1 Masotti, Roger
A1 Mendoza, Sandra
A1 Moreau, Catherine
A1 Ceregido, Maria Angeles
A1 Ramirez, Shelly
A1 Said, Ansoyta
A1 Tavares-Da-Silva, Fernanda
A1 Shi, Jiayuan
A1 Tong, Tina
A1 Treanor, John
A1 Diazgranados, Carlos A
A1 Savarino, Stephen
YR 2021
UL http://medrxiv.org/content/early/2021/10/11/2021.10.08.21264302.abstract
AB Background This study evaluated the safety and immunogenicity of an AS03-adjuvanted SARS-CoV-2 recombinant protein candidate vaccine, CoV2 preS dTM.Methods This Phase 2, modified double-blind, parallel-group study (NCT04762680) was conducted in adults, including those at increased risk of severe COVID-19. Participants were randomised 1:1:1, stratified by age (18–59/≥60 years), rapid serodiagnostic test (positive/negative) and high-risk medical conditions (yes/no), to receive two injections (day [D]1 and D22) of 5μg, 10μg or 15μg of CoV2 preS dTM antigen with fixed AS03 content. Interim safety and reactogenicity results (to D43) and neutralising antibodies (NAbs) against the D614G variant are presented (primary objectives).Findings Of 722 participants enrolled and randomised between 24 February and 8 March 2021, 721 received ≥1 injections (5μg, n=240; 10μg, n=239; 15μg, n=242). Four participants reported unsolicited immediate adverse events (AEs), two were vaccine-related (investigator assessment). Five participants reported seven vaccine-related medically-attended AEs. No vaccine-related serious AEs and no AEs of special interest were reported. Solicited reactions (local and systemic) were reported at similar frequencies between study groups; these were mostly mild to moderate and transient, with higher frequency and intensity post-injection 2 than post-injection 1. In SARS-CoV-2 naïve participants at D36, 96·9%, 97.0% and 97·6% of participants had ≥4-fold-rise in NAb titres from baseline in the 5μg-, 10μg- and 15μg-dose groups, respectively. NAb titres increased with antigen dose in younger (GMTs: 2954, 3951 and 5142 for 5μg-, 10μg- and 15μg-dose groups) but not older adults (GMTs: 1628, 1393 and 1736, respectively). NAb titres in non-naïve adults after one injection were higher than titres after two injections in naïve adults.Interpretation Two injections of CoV2 preS dTM-AS03 demonstrated acceptable safety and reactogenicity, and robust immunogenicity in SARS-CoV-2 naïve and non-naïve adults. These results informed antigen dose selection for progression to Phase 3 evaluation of primary and booster vaccination.Competing Interest StatementSS, MB, ALC, AC, RMC, BF, YM, ER, NR, DVB, GdB, RC, MHG, DL, HJ, RM, SM, CM, CAD and SSv are Sanofi Pasteur employees and may hold stock options. RMC reports owning shareholder and vesting options in Sanofi Pasteur. Additionally, SS, RMC, GdB, CAD and SSv, are inventors on a pending patent application filed by Sanofi Pasteur and GlaxoSmithKline for the development of the CoV-2 dTM vaccine. LS, MK, MAC, and FTDS are employed by the GlaxoSmithKline (GSK) group of companies and hold restricted shares in the GSK group of companies. AJ was contracted by Sanofi Pasteur and DD received funding from Sanofi Pasteur for his institution, George Washington University, to serve as a clinical site for the vaccine trial; and a percentage of university salary is allocated from this budget. NG reports receiving funding and study materials from Sanofi and funding from NIAID through the the COVID-19 Prevention Network (CoVPN) which provides research grants to her institution the Fred Hutchinson Cancer Research Center. MCK received NIAID funding support for the current study, paid to the clinical trials site for the COVID-19 prevention network and HIV vaccine trails network; Sanofi Pasteur contracted the site to conduct this clinical trial. DMR received a research grant from Sanofi Pasteur for this study. OO received a Gilead Sciences paid grant to Yale, and consulting fees from Gilead Sciences. OO also reports that Gilead, Integrity CE and Medscape paid for lectures, presentations, manuscript writing or educational events and that Gilead and VIIV paid for participation on a data safety monitoring or advisory board. VNR received funding from Sanofi for the CoVPN and Vaccine Treatment and Evaluation Units (VTEU) for COVID-19 vaccine clinical trials, and payments from Pfizer to her institution for the conduct of COVID-19 vaccine clinical trials. RS received clinical trial investigator site contracts with AES Synexus. NGR received a grant from Sanofi Pasteur to conduct this study and received grants from Sanofi, Merck, Pfizer, Quidel, Lilly in the past 36 months. NGR received a payment from IDAC and participated on an advisory board or safety monitoring for Micron, ICON and EMMES and reports having a leadership or fiduciary role (paid or unpaid) for IDSA, VTEU and ARLG. LDS received a research grant from Sanofi Pasteur and SRW and JW were contracted by Sanofi Pasteur. Authors report receiving funding from the US government through BARDA and the NIH for the clinical trial. AB, BE, NM, SM, MKJ, SR, JS, TT and JT declare no conflict of interest. The views presented here are those of the authors and do not purport to represent those of the Department of the Army.Clinical TrialNCT04762680Funding StatementSanofi Pasteur and Biomedical Advanced Research and Development Authority (BARDA)Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:https://www.advarra.com and Comite De Etica ZuguemeI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesQualified researchers can request access to patient-level data and related study documents, including the clinical study report, study protocol with any amendments, blank case report forms, statistical analysis plan, and dataset specifications. Patient-level data will be anonymised and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at https://www.clinicalstudydatarequest.com. https://www.clinicalstudydatarequest.com